Szpital Miejski Specjalistyczny Im. Gabriela Narutowicza W Krakowie
- Address
- Ul. Pradnicka 35-37, 31-202 Krakow, Poland
Oncology and Neoplasms
At Szpital Miejski Specjalistyczny Im. Gabriela Narutowicza W Krakowie, the clinical research portfolio focuses on cancer care within clinical oncology and chemotherapy. The trials are centered on evaluating new treatment options for patients with advanced and difficult-to-treat malignancies, with an emphasis on improving survival and disease control.
- Studies in advanced hepatocellular carcinoma are assessing whether new immunotherapy and anti-cancer treatment combinations can improve outcomes for people with liver cancer.
- Research in low-grade upper tract urothelial cancer is examining a novel tumor-ablative therapy aimed at better local disease management.
- The site’s work reflects a strong interest in testing innovative approaches that may expand treatment choices for patients with urothelial and liver cancers.
Overall, the research at this hospital is directed toward finding more effective therapies for solid tumors, while also helping clarify how newer cancer treatments perform in real patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Miejski Specjalistyczny Im. Gabriela Narutowicza W Krakowie
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01) | AstraZeneca AB | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2026-03-18 | 2026-03-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.